Transmedics Group shares surge 14.67% in premarket after Q2 revenue growth and FDA approval for Next-Gen OCS™ Lung trial.

Transmedics Group, Inc. surged 14.67% in premarket trading, driven by a 38% year-over-year revenue increase to $157.4 million for Q2 2025, exceeding market expectations. Additionally, the U.S. FDA conditionally approved the company's Next-Gen OCS™ Lung clinical trial, and Transmedics raised its 2025 full-year revenue guidance to $585 million to $605 million, with an expected year-over-year growth of 35% and an end-of-year cash balance exceeding $400 million.